Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx
<p>Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TA...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , |
| Publicado: |
2025
|
| Materias: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1849927636771405824 |
|---|---|
| author | Soyoung Kim (117362) |
| author2 | Ik-Hwan Han (8605281) Suin Lee (22678667) Sujin Park (2743) Jae-Won Jeon (560295) Hyunsu Bae (313407) |
| author2_role | author author author author author |
| author_facet | Soyoung Kim (117362) Ik-Hwan Han (8605281) Suin Lee (22678667) Sujin Park (2743) Jae-Won Jeon (560295) Hyunsu Bae (313407) |
| author_role | author |
| dc.creator.none.fl_str_mv | Soyoung Kim (117362) Ik-Hwan Han (8605281) Suin Lee (22678667) Sujin Park (2743) Jae-Won Jeon (560295) Hyunsu Bae (313407) |
| dc.date.none.fl_str_mv | 2025-11-25T05:10:50Z |
| dc.identifier.none.fl_str_mv | 10.3389/fonc.2025.1698857.s001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_1_The_CD300c_antibody_CL7_suppresses_tumor_growth_by_regulating_the_tumor_microenvironment_in_non-small_cell_lung_carcinoma_docx/30703346 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Oncology and Carcinogenesis not elsewhere classified non-small cell lung carcinoma CD300c CL7 tumor-associated macrophage tumor microenvironment immunotherapy |
| dc.title.none.fl_str_mv | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8<sup>+</sup> T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_3ede91df0956aa38d962093210d26027 |
| identifier_str_mv | 10.3389/fonc.2025.1698857.s001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30703346 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docxSoyoung Kim (117362)Ik-Hwan Han (8605281)Suin Lee (22678667)Sujin Park (2743)Jae-Won Jeon (560295)Hyunsu Bae (313407)Oncology and Carcinogenesis not elsewhere classifiednon-small cell lung carcinomaCD300cCL7tumor-associated macrophagetumor microenvironmentimmunotherapy<p>Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8<sup>+</sup> T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity.</p>2025-11-25T05:10:50ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fonc.2025.1698857.s001https://figshare.com/articles/dataset/Table_1_The_CD300c_antibody_CL7_suppresses_tumor_growth_by_regulating_the_tumor_microenvironment_in_non-small_cell_lung_carcinoma_docx/30703346CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307033462025-11-25T05:10:50Z |
| spellingShingle | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx Soyoung Kim (117362) Oncology and Carcinogenesis not elsewhere classified non-small cell lung carcinoma CD300c CL7 tumor-associated macrophage tumor microenvironment immunotherapy |
| status_str | publishedVersion |
| title | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx |
| title_full | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx |
| title_fullStr | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx |
| title_full_unstemmed | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx |
| title_short | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx |
| title_sort | Table 1_The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.docx |
| topic | Oncology and Carcinogenesis not elsewhere classified non-small cell lung carcinoma CD300c CL7 tumor-associated macrophage tumor microenvironment immunotherapy |